JP2007501800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501800A5 JP2007501800A5 JP2006522776A JP2006522776A JP2007501800A5 JP 2007501800 A5 JP2007501800 A5 JP 2007501800A5 JP 2006522776 A JP2006522776 A JP 2006522776A JP 2006522776 A JP2006522776 A JP 2006522776A JP 2007501800 A5 JP2007501800 A5 JP 2007501800A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- alkyl
- group
- lower alkyl
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49313803P | 2003-08-07 | 2003-08-07 | |
| US53373403P | 2003-12-31 | 2003-12-31 | |
| PCT/US2004/025564 WO2005013949A2 (en) | 2003-08-07 | 2004-08-06 | Method for treating cachexia with retinoid ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007501800A JP2007501800A (ja) | 2007-02-01 |
| JP2007501800A5 true JP2007501800A5 (cg-RX-API-DMAC7.html) | 2007-09-20 |
Family
ID=34138739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522776A Pending JP2007501800A (ja) | 2003-08-07 | 2004-08-06 | レチノイドリガンドを用いて悪液質を処置するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1653939A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007501800A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004263156B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2535260A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005013949A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009510114A (ja) | 2005-09-30 | 2009-03-12 | ビテ ファーマシューティカルズ， インコーポレイテッド | 特定のｒｘｒアゴニストによる癌治療 |
| ATE510536T1 (de) * | 2006-08-16 | 2011-06-15 | Action Medicines Sl | Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen |
| EP2451455A4 (en) * | 2009-07-10 | 2013-01-16 | Univ Case Western Reserve | RXR AGONIST COMPOUNDS AND METHODS |
| EP2556827A1 (en) * | 2011-08-11 | 2013-02-13 | Acadia Pharmaceuticals Inc. | Treatment of neurodegenerative diseases |
| CA2848540A1 (en) | 2011-09-15 | 2013-03-21 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Therapeutic compounds |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| MX352727B (es) | 2011-12-13 | 2017-12-06 | Dartmouth College | Tratamiento de trastorno autoinmune al usar agonistas de rxr. |
| TWI742513B (zh) | 2013-11-18 | 2021-10-11 | 美商弗瑪治療公司 | 作為bet溴域抑制劑之四氫喹啉組成物 |
| CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
| DK3426303T3 (da) * | 2016-03-10 | 2022-09-19 | Io Therapeutics Inc | Behandling af muskellidelser med kombinationer af rxr-agonister og thyroideahormoner |
| CN115252789A (zh) | 2016-03-10 | 2022-11-01 | Io治疗公司 | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 |
| US10238626B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| US10238655B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Dihydroindene and tetrahydronaphthalene compounds |
| US10231947B2 (en) | 2017-01-23 | 2019-03-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Isochroman compounds and methods of use thereof |
| WO2019060600A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| AU2022408160A1 (en) | 2021-12-07 | 2024-06-06 | Board Of Regents, The University Of Texas System | Use of an rxr agonist and taxanes in treating her2+ cancers |
| US11998521B2 (en) | 2021-12-07 | 2024-06-04 | Io Therapeutics, Inc. | Use of an RXR agonist in treating drug resistant HER2+ cancers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6320074B1 (en) * | 1992-04-22 | 2001-11-20 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
| HU218268B (hu) * | 1994-08-10 | 2000-06-28 | F.Hoffmann-La Roche Ag. | Retinsav X-receptor ligandok |
| IL116259A (en) * | 1994-12-19 | 2000-07-16 | American Cyanamid Co | Analogs of 9-cis retinoic acid and their use |
| US5917082A (en) * | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
| US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
-
2004
- 2004-08-06 AU AU2004263156A patent/AU2004263156B2/en not_active Ceased
- 2004-08-06 JP JP2006522776A patent/JP2007501800A/ja active Pending
- 2004-08-06 WO PCT/US2004/025564 patent/WO2005013949A2/en not_active Ceased
- 2004-08-06 CA CA002535260A patent/CA2535260A1/en not_active Abandoned
- 2004-08-06 EP EP04780406A patent/EP1653939A2/en not_active Withdrawn